Michael Cherny
Stock Analyst at B of A Securities
(4.41)
# 354
Out of 5,114 analysts
113
Total ratings
63.22%
Success rate
15.06%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVS CVS Health | Maintains: Buy | $100 → $95 | $74.44 | +27.62% | 12 | Jan 27, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $43.73 | +9.76% | 1 | Jan 12, 2026 | |
| CERT Certara | Upgrades: Outperform | $13 | $9.26 | +40.39% | 2 | Jan 6, 2026 | |
| DGX Quest Diagnostics | Maintains: Outperform | $203 → $210 | $182.35 | +15.16% | 3 | Oct 21, 2025 | |
| MCK McKesson | Maintains: Outperform | $785 → $850 | $822.30 | +3.37% | 15 | Sep 24, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $188 → $186 | $211.23 | -11.94% | 13 | Aug 12, 2025 | |
| PGNY Progyny | Upgrades: Outperform | $28 | $24.10 | +16.21% | 11 | Jul 8, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.19 | +152.10% | 2 | May 28, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $23.39 | -1.67% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $593.07 | -44.36% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $40 | $29.87 | +33.91% | 10 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $90 | $38.63 | +132.98% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $164.12 | +70.61% | 3 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $74.33 | +13.01% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $235.62 | +5.25% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $185.83 | +37.22% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.28 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $352.10 | -21.90% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $269.81 | -3.64% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $2.41 | +232.64% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $5.70 | +198.25% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $2.17 | +2,319.35% | 2 | Jan 5, 2022 |
CVS Health
Jan 27, 2026
Maintains: Buy
Price Target: $100 → $95
Current: $74.44
Upside: +27.62%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $43.73
Upside: +9.76%
Certara
Jan 6, 2026
Upgrades: Outperform
Price Target: $13
Current: $9.26
Upside: +40.39%
Quest Diagnostics
Oct 21, 2025
Maintains: Outperform
Price Target: $203 → $210
Current: $182.35
Upside: +15.16%
McKesson
Sep 24, 2025
Maintains: Outperform
Price Target: $785 → $850
Current: $822.30
Upside: +3.37%
Cardinal Health
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $211.23
Upside: -11.94%
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $24.10
Upside: +16.21%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.19
Upside: +152.10%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $23.39
Upside: -1.67%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $593.07
Upside: -44.36%
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $29.87
Upside: +33.91%
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $38.63
Upside: +132.98%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $164.12
Upside: +70.61%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $74.33
Upside: +13.01%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $235.62
Upside: +5.25%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $185.83
Upside: +37.22%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $12.28
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $352.10
Upside: -21.90%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $269.81
Upside: -3.64%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $2.41
Upside: +232.64%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $5.70
Upside: +198.25%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $2.17
Upside: +2,319.35%